Canada Markets open in 3 hrs 24 mins

Syros Pharmaceuticals, Inc. (0S9.F)

Frankfurt - Frankfurt Delayed Price. Currency in EUR
Add to watchlist
0.80120.0000 (0.00%)
As of 10:26AM CEST. Market open.
Full screen
Previous Close0.8012
Open0.7902
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.7902 - 0.8600
52 Week Range0.7206 - 40.0000
Volume18,532
Avg. Volume83
Market Cap49.632M
Beta (5Y Monthly)1.87
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Business Wire

    Syros Announces Closing of Merger with Tyme Technologies and Concurrent Private Placement

    CAMBRIDGE, Mass., September 16, 2022--Syros Pharmaceuticals, Inc. (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced the closing of its merger with Tyme Technologies, Inc., pursuant to which Syros acquired TYME, including its pipeline assets and net cash at closing of approximately $60 million. Shares of the combined company will trade on Nasdaq under the ticker symbol "SYRS."

  • GlobeNewswire

    Syros and Tyme Technologies Announce Stockholder Approval of Merger

    -- Combined Company to Trade on Nasdaq Under Ticker “SYRS” ---- Syros Announces 1-for-10 Reverse Stock Split of Common Stock -- CAMBRIDGE, Mass. and BEDMINSTER, N.J., Sept. 15, 2022 (GLOBE NEWSWIRE) -- Syros Pharmaceuticals, Inc. (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, and Tyme Technologies, Inc. (NASDAQ:TYME) today announced the results of the special meetings of the stockholders of Syros and TYME, respectively, each held on September 15, 20

  • Business Wire

    Syros Receives FDA Orphan Drug Designation for SY-5609 for the Treatment of Pancreatic Cancer

    CAMBRIDGE, Mass., September 13, 2022--Syros Pharmaceuticals, Inc. (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation (ODD) to SY-5609 for the treatment of pancreatic cancer. SY-5609, a highly selective and potent oral cyclin-dependent kinase 7 (CDK7) inhibitor, is currently being evaluated in combination with chemotherapy for the treatment of patients wi